ReviewWorld journal of clinical cases2021
Gut microbiota and inflammatory bowel disease: The current status and perspectives.
Review in World journal of clinical cases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Gut Microbiota Alterations and Dysbiosis Patterns in Pediatric Inflammatory Bowel Disease: Clinical Correlations and Therapeutic Impact.Journal of clinical medicine · 2026Article
- The melatonin-microbiome axis: a new frontier in gut health for the immunomodulatory, antioxidant and anti-inflammatory properties.Inflammopharmacology · 2026Review
- Metabolic modeling of microbial communities in the chicken ceca reveals a landscape of competition and co-operation.Microbiome · 2025Article
- Microalgal-enhanced cerium oxide nanotherapeutics for alleviating inflammatory bowel disease via scavenging reactive oxygen species and modulating gut microbiota in colitis.Materials today. Bio · 2025Article
- Gut microbiota differences in children classified by extreme physical fitness and physical activity levels from a Chinese Cross-Sectional study.Scientific reports · 2025Article
- Oxidative Stress, Gut Bacteria, and Microalgae: A Holistic Approach to Manage Inflammatory Bowel Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Fecal Microbiota Transplantation for Chronic Pouchitis: A Systematic Review and Meta-Analysis.Microorganisms · 2024Review
- Unveiling the overlooked fungi: the vital of gut fungi in inflammatory bowel disease and colorectal cancer.Gut pathogens · 2024Review
- Research trends of next generation probiotics.Food science and biotechnology · 2024Review
- Inflammatory Bowel Disease and Cardiovascular Disease: An Integrative Review With a Focus on the Gut Microbiome.Cureus · 2024Review
- Benzyl Isothiocyanate and Resveratrol Synergistically Alleviate Dextran Sulfate Sodium-Induced Colitis in Mice.Foods (Basel, Switzerland) · 2024Article
- AnJournal of bacteriology · 2024Article
- The Networked Interaction between Probiotics and Intestine in Health and Disease: A Promising Success Story.Microorganisms · 2024Review
- An integrative multi-omic analysis defines gut microbiota, mycobiota, and metabolic fingerprints in ulcerative colitis patients.Frontiers in cellular and infection microbiology · 2024Article
- Knowledge, attitude, and practice of patients living with inflammatory bowel disease: A cross-sectional study.World journal of gastroenterology · 2023Article
- An In Vitro Medium for Modeling Gut Dysbiosis Associated with Cystic Fibrosis.bioRxiv : the preprint server for biology · 2023Article
- Article
- Intestinal Microbiota and miRNA in IBD: A Narrative Review about Discoveries and Perspectives for the Future.International journal of molecular sciences · 2023Review
- Role ofNutrients · 2023Review
- Carotenoids and Their Health Benefits as Derived via Their Interactions with Gut Microbiota.Advances in nutrition (Bethesda, Md.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic immune-mediated disease that affects the gastrointestinal tract. It is argued that environment, microbiome, and immune-mediated factors interact in a genetically susceptible host to trigger IBD. Recently, there has been increased interest in the development, progression, and treatment of IBD because of our understanding of the microbiome. Researchers have proved that some factors can alter the microbiome and the pathogenesis of IBD. As a result, there has been increasing interest in the application of probiotics, prebiotics, antibiotics, fecal microbiota transplantation, and gene manipulation in treating IBD because of the possible curative effect of microbiome-modulating interventions. In this review, we summarize the findings from human and animal studies and discuss the effect of the gut microbiome in treating patients with IBD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.